GeneralConnection.com ➔ Dictionary
Dictionary Search

modifier gene

Synonyms

Noun

1. modifier

2. gene, cistron, factor

Usage
Gene x environment interaction analysis confirms genetic modifier effects on steroid efficacy via TGF-β pathway in Duchenne muscular dystrophy - Nature
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Survey Study Highlights Interest, Motivations Behind Modifier Gene Testing for Huntington Disease - NeurologyLive
Huntington’s disease LIG1 modifier variant increases ligase fidelity and suppresses somatic CAG repeat expansion - PNAS
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion - GlobeNewswire
A genetic screen for modifiers of cohesin clustering identifies regulators of genome folding - Science | AAAS
Resetting retinal networks with a gene-agnostic approach - Drug Target Review
Redefining Genetic Disease ‘Carriers’: Beyond Simple Transmitters to Real Health Impacts - 3billion
EyeWorld Weekly, March 27, 2026 - EyeWorld
Ocugen, Inc. to Present Innovative Modifier Gene Therapy Platform at May 2026 Conferences - Quiver Quantitative
A novel modifier gene therapy to treat Stargardt disease: Phase 1 GARDian1 Trial Insights | Eye - Nature
Single-cell RNA-sequencing co-expression analysis with CFTR and CF modifier genes in lung tissue - Nature
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy - Ocugen, Inc.
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa - GlobeNewswire
Genomic modifiers of malignant and neurodevelopmental phenotypes in individuals with PTEN hamartoma tumor syndrome - Nature
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease - Ocugen, Inc.
Genetic mapping identifies Homer1 as a developmental modifier of attention - Nature
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data - Ocugen, Inc.
Genetic analysis points to new clues behind pain in cystic fibrosis - Cystic Fibrosis News Today
Ocugen to Participate in Upcoming July Industry Conferences - The Manila Times
Network-aware self-supervised learning enables high-content phenotypic screening for genetic modifiers of neuronal activity dynamics - Nature
Ocugen’s Gene Therapy OCU410ST Continues to Show Efficacy in Phase 1 Stargardt Disease Trial - CGTLive®
The sex-biased chromatin modifier SMC1A promotes autoimmunity by shaping inflammatory pathways in patients with SLE - Nature
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST—Modifier Gene Therapy for Stargardt Disease - Ocugen, Inc.
Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Yahoo Finance
Dry AMD gene therapy data takes center stage in Ocugen's March 24 webcast - Stock Titan
Ocugen doses first subject in trial of modifier gene therapy candidate - Clinical Trials Arena
Controlling DNA Scanning Machines to Slow Expansion of CAG Repeats - HDBuzz
Ocugen moving AMD-linked vision loss gene therapy to Phase III - FirstWord Pharma
Ocugen brings blindness gene therapy to two May events in 2026 - Stock Titan
Italian research discovers cardiac risk modifier gene - Il Sole 24 ORE
Potential one-time RP gene therapy moves closer as Ocugen fills major trial - Stock Titan
First Patient Dosed in Phase 2/3 GARDian3 Trial of OCU410ST for Stargardt Disease - CGTLive®
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen, Inc.
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress - Ocugen, Inc.
A mutation-independent approach for muscular dystrophy via upregulation of a modifier gene - Nature
ALG6 acts as a modifier gene in the inherited genetic eye disease retinitis pigmentosa 59 - The University of Alabama at Birmingham
Modifier variants in metabolic pathways are associated with an increased penetrance of Leber’s Hereditary Optic Neuropathy - Nature
3 BLAs in 3 Years: Ocugen Sees Potential in Eye Disease Gene Therapies - Genetic Engineering and Biotechnology News
The genetic modifier approach: identifying the right target for rare diseases - Drug Target Review
A genetic variant in SMAD7 acts as a modifier of LMNA-associated muscular dystrophy, implicating SMAD signaling as a therapeutic target - Science | AAAS
TAS2R38 is a novel modifier gene in patients with cystic fibrosis - Nature
In vivo CRISPR–Cas9 genome editing in mice identifies genetic modifiers of somatic CAG repeat instability in Huntington’s disease - Nature
Modifier gene therapy - clinical development and manufacturing considerations - European Pharmaceutical Review
Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease - Ocugen, Inc.
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation - Nature
Whole-exome sequencing reveals the genetic causes and modifiers of moyamoya syndrome - Nature
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024 - Ocugen, Inc.
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 - Ocugen, Inc.
Expression level is a major modifier of the fitness landscape of a protein coding gene - Nature
Long-term potential revealed for novel modifier gene therapy - European Pharmaceutical Review
Retinoic acid related orphan receptor α is a genetic modifier that rescues retinal degeneration in a mouse model of Stargardt disease and Dry AMD - Nature
Is HSPG2 a modifier gene for Marfan syndrome? - Nature
Tipping the balance; new insights into HD genetic modifiers - HDBuzz
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea - Ocugen, Inc.
Genetic modifiers of somatic expansion and clinical phenotypes in Huntington’s disease highlight shared and tissue-specific effects - Nature
SCN4A as modifier gene in patients with myotonic dystrophy type 2 - Nature
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design - Ocugen, Inc.
Genetic modifiers of rare variants in monogenic developmental disorder loci - Nature
Genetic modifiers may influence CF disease course: Review - Cystic Fibrosis News Today
How a gene-agnostic approach opens doors to new therapeutics - Ophthalmology Times Europe
Kcnn4 is a modifier gene of intestinal cystic fibrosis preventing lethality in the Cftr -F508del mouse - Nature
Is it time for genetic modifiers to predict prognosis in Duchenne muscular dystrophy? - Nature
Oligogenic inheritance of a human heart disease involving a genetic modifier - Science | AAAS
Ocugen’s Modifier Gene Therapy Platform Takes Center Stage at Three June Conferences () - aktiencheck.de
Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication - Ocugen, Inc.
Genomic diversity in functionally relevant genes modifies neurodevelopmental versus neoplastic risks in individuals with germline PTEN variants - Nature
Breakdown of self-incompatibility due to genetic interaction between a specific S -allele and an unlinked modifier - Nature
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) - Ocugen, Inc.
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease - Ocugen, Inc.
From Flies to Families: How a Gene Variant May Shield Against Seizures - the-scientist.com
Quantitative trait locus mapping identifies the Gpnmb gene as a modifier of mouse macrophage lysosome function - Nature
Predicting the Severity of Cardiomyopathy via Genetic Modifiers - Northwestern University
Differential intron retention in Jumonji chromatin modifier genes is implicated in reptile temperature-dependent sex determination - Science | AAAS
Huntington's Disease Therapeutics Conference 2025 – Day 2 - HDBuzz
Copy number variants as modifiers of breast cancer risk for BRCA1 BRCA2 pathogenic variant carriers - Nature
Mutations in the chromatin modifier gene KANSL1 cause the 17q21.31 microdeletion syndrome - Nature
TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospects | npj Breast Cancer - Nature
EMA provides positive ATMP opinion for gene therapy products OCU410 and OCU410ST - Ophthalmology Times Europe
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication - Ocugen, Inc.
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers - Nature
The histone modifier KAT2A presents a selective target in a subset of well-differentiated microsatellite-stable colorectal cancers | Cell Death & Differentiation - Nature
Ocugen’s Retinitis Pigmentosa Gene Therapy OCU400 Sustains or Improves Visual Function in 2-Year Follow-Up Data - CGTLive®
Inside The Trials Aiming To Stop Vision Loss For Rare Eye Disease Patients - Clinical Leader
The autism-associated chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment - Nature
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen, Inc.
DNA repair genes drive Huntington's disease, UCLA study finds - Drug Target Review
Modifier gene may explain why some with cystic fibrosis are less prone to infection - EurekAlert!
Exome Sequencing Reveals Immune Genes as Susceptibility Modifiers in Individuals with α - Nature
Variants within the SP110 nuclear body protein modify risk of canine degenerative myelopathy - PNAS
Recruiting modifiers - Nature
Mystery solved: New study reveals how DNA repair genes play a major role in Huntington's disease - UCLA Health
Genetic Causes and Modifiers of Autism Spectrum Disorder - Frontiers
Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy - Ocugen, Inc.
Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis - Nature
Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa - Ocugen, Inc.
The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy - Nature
Ocugen Announces Positive Opinion of European Medicines Agency’s Committee for Advanced Therapies for Advanced Therapy Medicinal Product Classification for Modifier Gene Therapy Candidate OCU400 for Retinitis Pigmentosa - Ocugen, Inc.
Nature Gene Therapy publishes preclinical data of Ocugen's OCU400 genetic modifier - EurekAlert!
Foreign Language Equivalents
Foreign Language Equivalents of 'modifier gene'
Language Equivalent   Language Equivalent
French    Spanish
Misspellings - Typos
modufier gene,   mpdifier gene,   modifer gene,   modidier gene,   modifier fene,   moidfier gene,   nodifier gene,   modigier gene,   modifieer gene,   modifir gene,   modifior gene,   modifuer gene,   modifier geme,   modifie rgene,   modifier genr,   modifiee gene,   modiifier gene,   modifiet gene,   mdoifier gene,   modifier grne,   modifier gnee,   moifier gene,   modifier genee,   modifier gne,   modifirr gene,   moddifier gene,   modifier geene,   modifie gene,   modifier gebe,   mofifier gene,   modifier geen,   modiier gene,   modifier gee,   modfiier gene,   omdifier gene,   mosifier gene,   modifierg ene,   moodifier gene,   modifier gen,   ,odifier gene,   modiffier gene,   modifiwr gene,   modofier gene,   modfier gene,   modifier genw,   modifire gene,   midifier gene,   modifier gwne,   modifoer gene,   modifierr gene,   modifier egne,   modifier ggene,   odifier gene,   modifiier gene,   modiifer gene,   modifier genne,   modifeir gene,   modifiergene,   mdifier gene,   modifier ene,   modifier gene,   mmodifier gene,   modifier hene
Words Starting with Letter - 'A'
a a battery a billion
a bit a bit much a capella singing
a cappella singing a couple of a few
a fortiori a good deal a great deal
a horizon a hundred a hundred and one
a hundred thousand a hundred times a kempis
a la carte a la mode a level
a little a lot a million
Go to Page 1              Go to Page 2 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z